Two preparations of yellow fever vaccine (17D) were studied by clonal analysis. From one (17D-England) three types of clones were isolated, each differentiated by plaque size in Vero cells and virulence for intracerebrally inoculated mice: small plaque (SP) and large plaque (LP) clones were lethal, whereas medium plaque (MP) clones failed to kill at doses up to 10 6 p.f.u. Analysis of 24 randomly selected clones showed the original vaccine to be a mixture of predominantly MP and SP variants; 58% and 42% respectively. A single passage in suckling mice modified this composition to 90% SP and 10% LP variants. The response of six inbred strains of mice to intracerebral inoculation of the MP variant varied from complete resistance to complete susceptibility. From another 17D substrain (17D-South Africa) two types of variants were isolated (a SP avirulent type and a LP type of intermediate virulence), both different from the previously described variant.
INTRODUCTION
Despite being one of the most successful live-virus vaccine, the 17D strain of yellow fever virus (YFV) has never been fully characterized genetically. This is probably a reflection of the safety and effectiveness of this vaccine, exhaustively established well before the introduction of the tissue culture methodology required for genetic studies. Like any other virus population, 17D has a potential to undergo changes in its properties. By passage in an unnatural host such as continuous cell line or mouse brain, a decrease or enhancement of its neurovirulence has been demonstrated (Theiler, 1951; Hallauer, 195 9; Collier et al., 195 9) . More important, modifications of the properties of the original 17D strain had also been observed following passage in chick embryo, the host in which the vaccine is currently produced. Some independently derived substrains of the vaccine had been shown to be either of reduced immunogenicity, failing to produce immunity consistently in vaccinated persons, or to possess an enhanced degree of neurotropism, associated with an increased incidence of post-vaccinal reactions of encephalitic type (Fox et al., 1942; Fox & Penna, 1943) . The latter episode prompted the introduction of a seed-lot system to minimize the number of subcultures required for the production of the vaccine. Nevertheless, the number of passages that the seed has undergone varies from one institute to another (World Health Organization, 1971) . As this WHO report suggests, standardization of the world production is advisable, and for this purpose the best substrain among those currently in use should be selected. The possible heterogeneity of the seeds must be taken into consideration as an additional cause of differences and source of variability. In the present study two 17D strains from different ~" Present address: Centro de Microbiologia y Biologia Celular, I.V.I.C., Apartado 1827, Caracas 1010A, Venezuela.
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METHODS
Virus strains. 17D vaccine was obtained in lyophilized form from two sources. (i) YF standard virus preparation Batch YFX1 courtesy of Mr R. Ferris, WeUcome Research Laboratories. This is a reference standard preparation of the vaccine, used to control titrations of virus (Burfoot et al., 1977) . It contains 17D-YFV at the 233rd chick embryo passage. (ii) 'YF vaccine Batch No. 10402' kindly provided by Dr J. Gear, South African National Institute of Virology. These vaccine substrains will be referred to respectively as 17D-E and 17D-SA. Assays were performed either with virus from freshly reconstituted ampoules of the vaccines, or with frozen samples of one ampoule of each type (i and ii) reconstituted respectively in 6 and 5 ml of 0.75% (w/v) bovine plasma albumin in phosphate-buffered saline pH 7.3 (BPA-PBS). These preparations had titres of 104 and 105 p.f.u./ml respectively in Vero cells and showed a plaque-size distribution similar to virus from freshly reconstituted ampoules. First suckling mouse brain passages of the 17D substrains or of isolated clones were prepared as 10 % (w/v) suspensions of infected brains in BPA-PBS.
Virus assay. The technique used was, with minor modifications, that described by Burfoot et al. (1977) for testing the potency of the 17D vaccine. Confluent cultures of Vero cells, grown in 50 mm Petri dishes or Linbro multi-well plastic culture vessels (Fb-6-TC, FB-16-24TC purchased from Flow Laboratories), were inoculated with virus dilutions. After adsorption for 2 h at 36 °C in a humidified incubator, monolayers were overlaid with 1% sodium carboxymethylcellulose (CMC, Koch-Light) in Eagle's minimal essential medium (MEM), plus 2.5% foetal calf serum (FCS), antibiotics and 20 mM-NaHCOa. After 6 days incubation at 36 °C in an atmosphere of 5 % CO2 in air, cell sheets were fixed with formol saline, stained with crystal violet, and plaques counted.
Cloning procedure. Preformed Vero cell monolayers grown in 24-well tissue culture vessels were inoculated with 0.02 ml virus dilutions containing approx. 2, 1 or 0.5 p.f.u, and treated as for conventional plaque assay (see above). After 6 days incubation supernatant fluid from each well was separately removed and stored. Cultures were then fixed, washed and stained. Infectivity in supernatant fluids from cultures with a single plaque were considered plaque-purified clones. For selected clones the process was repeated twice more without intermediate amplification. Yields from individual plaques ranged between 5 × 102 and 105 p.f.u. Working stocks of each clone were prepared by a single passage in Vero cells, grown in Petri dishes, each inoculated with 0.1 ml of the undiluted original clone. Supernatant fluids from wells without visible plaques (i.e. < 5 p.f.u./ml) were passaged in Vero cells; no plaques were produced.
Plaque size of measurements. These were made using a Polaron x 10 lens, equipped with a measuring graticule with subdivisions of 0.1 mm (Polaron Equipments Ltd., London). Plaque diameters were measured using 0.2 mm intervals. Differences in the mean plaque diameter (m.p.d.), calculated from 50 to 100 plaques from at least two monolayers, were tested by Student's t-test. Clones or other virus samples were classified according to their plaque size by comparison with prototype variants of each size included in the assay.
Mice. Unless otherwise specified growth of virus stocks and titrations of virus samples were made in Swiss albino random bred mice (LACA strain) from the breeding colony of the Microbiology Department of Reading University. Inbred mice 5 to 7 weeks old (strains Baib/c, C57B1/10, DBA/2 AKR, C3H/He, A) were purchased from OLAC, Blackthorn, Bicester, Oxon., U.K. Suckling (2 to 4 days old) and adult (5 to 7 weeks old) mice were inoculated intracerebrally (i.c.) with 0.01 ml and 0.03 ml of virus suspensions respectively. In virulence experiments all mice surviving the primary inoculation were challenged 3 weeks later by i.c. inoculation of 3000 p.f.u, of the first suckling mouse brain passage of the 17D-E substrain (17D-E1), a dose which regularly killed 100% of previously uninfected mice. In all experiments an uninfected group of mice was challenged in parallel to confirm the lethal response. Median lethal doses (LDs0) were calculated by the Spearman-Karber method (Dougherty, 1964 ) from mice which died between the 5th day after infection and the challenge. Mice which died after the challenge were scored as not infected. Mice which survived the challenge were scored as protected. The number of animals killed by the primary inoculation plus those protected against challenge was used for calculating the median infectious dose (IDs0).
RESULTS

Plaque variants from 17D-E
When plated on Vero cells both the original 17D-E substrain and its first suckling mouse brain passage (17D-E1) produced a distinctly mixed population of plaques, in which at least two basic types could be differentiated: a small size (<0.8 ram) and a larger one (>1 mm) ( Fig. 1 a, b) . The small plaque type comprised 45% of the 17D-E and 91% of the 17D-E~ populations of plaques. When plated simultaneously, selected clones of the smaller type from both preparations were indistinguishable. However, clones of the larger size isolated from 17D-E1 were significantly larger than those from 17D-E. These three types of plaque were therefore classified as small (SP), medium (MP) and large (LP) (Fig. 1 e, d , e). In the standard conditions (6 days incubation at 36 °C under 1% CMC) the mean plaque diameter ranged in different assays from 0.5 to 1 mm for the SP, 0-8 to 2 mm for the MP and 1.3 to 2.7 mm for the LP variant. Because of the small difference in plaque size between MP and LP variants their relative proportion in the 17D-E population could be estimated only through their relative frequencies of isolation. Of a total of 25 clones isolated from the 17D-E preparation, 24 were obtained by collecting the supernatant medium from all wells with a single plaque, without selection for a particular plaque size. Of these 10 (42%) were of SP phenotype and 14 (58 %) of MP phenotype. One of the isolated MP clones was probably contaminated with LP type virus (see below). The 25th clone, which eventually proved to be LP, was obtained by further plaque purification of the supernatant medium of a well with one large and five small plaques. Thus, LP variants amounted to 4 % (1/25) or less of the total 17D-E population.
Virulence for mice of the 17D-Eplaque variants
Representative clones of each plaque size, which had been plaque-purified three times, were titrated by i.c. inoculation in suckling and adult LACA mice. The three variants were equally lethal for suckling mice with LDs0 closely resembling p.f.u, values. In adult mice SP and LP clones were fully lethal (IDs0 = LDs0 ), in contrast to MP clones, which failed to kill at doses of up to 106 p.f.u., inducing instead a completely subclinical infection, detected by development of protection against a subsequent lethal challenge (Table 1) . To confirm on a wider basis this apparent correlation between plaque size and virulence, the collection of clones from both 17D-E and 17D-Ea was tested in mice. Stocks of each clone, obtained by a single passage in Vero cells of the original isolate were titrated in cells for determination of infectivity and plaque size and at least two consecutive dilutions of each stock were inoculated i.c. in groups of five or six adult mice. All 14 SP and 4 LP clones tested induced a uniform lethal response. Viruses recovered 8 to 13 days after infection from brains of paralysed mice had the same plaque size character as the inoculated virus. The SP and LP variants were differentiated by the in vivo response in that survival times were consistently shorter in mice inoculated with the LP variant (Fig. 2 ). These differences in survival time correlated with the ability of the LP variants to multiply faster and to reach higher infectivity levels in the brains of inoculated mice, as determined in comparative pathogenesis experiments (data not shown). Of the 14 MP clones tested, 12 induced a predominantly benign response (>80% protection) over a range of doses from 102 to l0 s p.f.u. Virus recovered 8 to 10 days after infection from mice without clinical signs was of the MP type and produced uniform protective response upon reinoculation in adult animals. The remaining two clones produced 80 to 100% mortality. This response was associated with the presence in the brain of paralysed animals of SP virus with one clone and of LP virus with the other. Results of i.c. titrations of the original vaccine were consistent with the presence of subpopulations of different virulence. In adult mice the vaccine produced a high proportion of inapparent infections more marked at low virus concentrations (Table 1) . Consequently, the resulting IDs0 values were more than tenfold higher than the LDso values.
Virulence of l 7D-E plaque variants for different strains of mice
Adult mice of six inbred strains were tested for susceptibility to i.c. inoculation of the MP and SP variants isolated from 17D-E. The response of mouse strains to the infection of the MP variant varied from complete resistance (C57B1/10, Balb/c, AKR), as previously observed with random-bred LACA mice, to intermediate (C3H/He) or high (DBA/2, A) susceptibility (Table 2) . Conversely, the SP variant induced in the three mouse strains tested an identical response both in terms of the outcome of infection (100% mortality) and of survival time.
Isolation of clones from 17D-SA
When plated on Vero cells the 17D vaccine produced in South Africa (17D-SA) consisted mainly of large plaques. A total of 18 clones was obtained by plaque purification. By direct comparison with the previously described plaque variants 17 were classified as LP and one as SP. From these the SP clone and two randomly chosen LP clones were selected for further plaque purification (twice more), amplified in Vero cells and their virulence tested by i.c. inoculation of adult mice (Table 1) . The 17D-SA-SP clone showed a consistently avirulent behaviour, similar to that exhibited by 17D-E-MP clones. Because of the similarity of the in vivo response elicited by these variants, their plaque sizes were compared in repeated occasions. Significant differences were confirmed in four out of five determinations. Both large plaque clones tested induced in mice a mixed response of death and protection over a range of doses from 101 to 104 p.f.u. Other LP clones, plaque-purified once, and the original vaccine produced a similar behaviour. In all cases tested virus recovered from the brains of dying animals was of the LP type. This type of response was not associated with a particular batch of animals, since it occurred on repeated occasions. Also, in parallel determinations 17D-E1-LP or 17D-E1-SP clones manifested their usual uniform lethality. Since it was produced by three times plaque-purified clones, the observed response was considered to be an intrinsic characteristic of these substrains, rather than the product of a mixed population.
DISCUSSION
Two vaccine preparations, originating from different seeds of the 17D strain of YFV, were found to contain variants with distinct biological characteristics. A subpopulation completely avirulent for adult mice was present in both vaccines, being differentiated in terms of plaque size, small in the 17D-SA variant, and medium in the 17D-E variant. The other variant isolated from 17D-SA, a LP type, exhibited in mice an irregular pathogenicity in contrast to the highly reproducible fully lethal response induced by the LP and SP clones isolated from 17D-E and 17D-E 1. Thus, within the limits of the small sample tested, and on the basis of the two characters studied, the two 17D vaccine preparations did not appear to share any subpopulation with a common phenotype. Other commercial 17D vaccine preparations (from Colombia, Brazil and U.S.A.), tested by the plaque assay system described here, each produced a unique plaque size distribution (F. Liprandi & R. Walder, unpublished observations) suggesting that variation between and within vaccines from different sources may be a rather general feature. This is not unexpected because of the different passage history of the various seeds of the vaccine (WHO, 1971) .
For the more extensively studied subpopulations isolated from 17D-E, a correlation was established between each plaque size character and a defined virulence behaviour in mice. The change in both of these properties observed with the two clones of the MP type upon a single passage in adult mouse was probably a consequence of heterogeneity present in the original isolate rather than mutation occurring during the amplification in Vero cells or replication in the brain~ since these procedures did not modify detectably three times-purified clones. Nevertheless, the MP variant, for which mouse brain probably represents a selective replicative substrate, could give rise to a virulent revertant as it was found with one MP clone (three times plaque-purified) upon repeated passages in suckling mouse brain or after a single passage in immunosuppressed adult mice (F. Liprandi, unpublished observations). In both cases reversion to virulence was associated with a change in plaque size, to the SP type, this co-variation further confirming the correlation between the two traits.
The fact that approx. 50% of the 17D-E infectivity consisted of a variant (MP) of limited neurotropism for mice was of particular interest. Intracerebral lethality for mice is considered a consistent property of the vaccine strain (Theiler & Smith, 1937) , to the extent that requirements of its potency according to the standards specified by the WHO (Bonnel, 1956) are expressed as i.c. LDs0 for adult mice. This criterion appears to be greatly dependent on the strain of mice employed, as shown by the different degrees of susceptibility to the MP variant found among various inbred strains of mice. This response was certainly not associated with the presence of the gene for resistance to flavivirus (Sabin, 1952) since these same'strains of mice have been shown to be susceptible to inoculation of the 17D vaccine strain (Darnell et at., 1974) . Although a direct isolation has not been described, there is, in previous reports, indirect evidence of the presence in the vaccine of a subpopulation completely avirulent for mice. Fox (1943) showed that six substrains of 17D, which had been used for vaccination in Brazil, differed markedly in the proportion of sublethal infections they produced in mice. This, for two substrains (17D low and 17D3) was sufficiently frequent to increase the infectivity titres by 25 % above the figures based on deaths alone. Interestingly enough, the only substrain which did not produce sublethal infections to any significant extent, was also highly encephalitogenic for primates (Fox & Penna, 1943) . Hallauer (1959) found that a 17D strain (produced in Holland) completely lost its i.c. pathogenicity for mice after two passages in KB cells, the change being stable over 40 passages in these cells. In monkeys inoculated i.c. or subcutaneously this derived virus was as effective as the parental 17D in conferring protection against a subcutaneous challenge with the virulent Asibi strain (Schindler & Hallauer, 1963) .
The status of the 17D vaccine as far as safety is concerned is certainly not a matter of controversy. Nevertheless, untoward reactions have happened, even if very sporadically (for review, see Stuart, 1956) . If a reappraisal of the vaccine does take place, the variation which appears to occur in the actual vaccine might be exploited for selecting those variants with optimum attributes, e.g. an even further reduced neurotropism for primates.
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